ORIGINAL RESEARCH
Oncology
doi: 10.25005/2074-0581-2026-28-2-364-373
IMMUNOLOGICAL PROFILE OF SEROUS OVARIAN CARCINOMA AND DUCTAL BREAST CARCINOMA

I.O. GOLOVKIN1, K.A. ALIEV1, T.P. MAKALISH1, E.R. ASANOVA1, P.E. MAKSIMOVA1,2, E.YU. ZYABLITSKAYA1

1Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University, Simferopol, Russian Federation
2Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation

Objective: To evaluate the immunological profile of serous ovarian carcinoma and ductal breast carcinoma, as well as the activity of apoptotic markers as a prognostic factor of sensitivity to immunotherapy.

Methods: The study included 53 patients with serous ovarian adenocarcinoma, stage II-III, or breast cancer T2-4N0-3M0-1, and 39 women in the control group with oophorectomy or breast fibroadenoma not associated with tumor pathology. The analysis included immunohistochemical determination of CD4+, CD8+, CD20+, and CD163+ cells, as well as bcl-2 and CD95 expression in tumor and healthy tissues. Statistical processing was performed using nonparametric statistical methods.

Results: CD8+ cytotoxic lymphocytes and CD163+ macrophages predominated in ovarian tumor tissue, and their number increased statistically significantly compared with conditionally healthy tissue. CD4+ T-helper cells were less common. A similar cell distribution was observed in the demarcation zone. In breast cancer, macrophages and T-helper cells were the most numerous. Expression of the anti-apoptotic marker bcl-2 was reduced in tumor tissue, whereas the pro-apoptotic marker CD95 showed high expression in both carcinoma localizations. These changes confirm the complex mechanisms of immunosuppression in the tumor microenvironment.

Conclusion: The immunological profile of serous ovarian carcinoma and breast cancer is characterized by pronounced infiltration of cytotoxic lymphocytes, T-helper cells, and macrophages, as well as changes in the expression of apoptotic markers. These data may be useful for optimizing ovarian cancer immunotherapy

Keywords: Ovarian cancer, breast cancer, tumor microenvironment, lymphocytic infiltration, macrophages.

Download file:

References
  1. Blanc-Durand F, Clemence Wei Xian L, Tan DSP. Targeting the immune microenvironment for ovarian cancer therapy. Front Immunol. 2023;14:1328651. https:// doi.org/10.3389/fimmu.2023.1328651
  2. Almeida-Nunes DL, Mendes-Frias A, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Immune tumor microenvironment in ovarian cancer ascites. Int J Mol Sci. 2022;23(18):10692. https://doi.org/10.3390/ijms231810692
  3. Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Tsibulak I, Cibula D, et al. LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC). Ann Oncol. 2022;33:S1397. https://doi.org/10.1016/j.annonc.2022.08.026
  4. Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39:1842-55. https://doi.org/10.1200/ JCO.21.00306
  5. Hao J, Yu H, Zhang T, An R, Xue Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: A systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920967241. https://doi. org/10.1177/1758835920967241
  6. Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapy for cancer: Progress and challenges. BioDrugs. 2013;27(5):453-68. https://doi.org/10.1007/ s40259-013-0030-9
  7. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17-35. https://doi.org/10.1016/j.immuni.2019.12.011
  8. Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021;39(7):928-44. https://doi. org/10.1016/j.ccell.2021.04.004
  9. Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095. https://doi.org/10.1038/ncomms15095
  10. Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022;40(5):545-57. https:// doi.org/10.1016/j.ccell.2022.03.008
  11. Chertkova AI, Kadagidze ZG, Zabotina TN, Kushlinskiy NE. Kletochnyy immunitet pri rake yaichnikov [Cell immunity for ovary cancer]. Voprosy biologicheskoy, meditsinskoy i farmatsevticheskoy khimii. 2019;22(1):3-12. Available from: https://doi.org/10.29296/25877313-2019-01-01
  12. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, Garbini F, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol. 2005;16(4):590-6. https://doi.org/10.1093/annonc/mdi112
  13. Antoneeva II. Differentsirovannye i aktivatsionnye markyory limfotsitov perifericheskoy krovi bol'nykh rakom yaichnikov v dinamike opukholevoy progressii [Differentiation-lymphocytes in the patients with ovarian cancer in the course of tumor progression]. Meditsinskaya immunologiya. 2007;6:649-52.
  14. Rodriguez GM, Galpin KJC, McCloskey CW, Vanderhyden BC. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers (Basel). 2018;10(8):242. https://doi.org/10.3390/cancers10080242
  15. Сolvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137. https://doi.org/10.3389/ fonc.2014.00137
  16. Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W, et al. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017;147(1):181-7. https://doi.org/10.1016/j.ygyno.2017.07.007
  17. Aliev KA, Zyablickaya EYu, Makalish TP, Sorokina LE, Asanova ER. Mekhanizmy lekarstvennoy ustoychivosti k neoad"yuvantnoy khimioterapii pri rake molochnoy zhelezy [Mechanisms of drug resistance to neoadjuvant chemo therapy in breast cancer]. Uspekhi molekulyarnoy onkologii. 2024;11(3):10. https://doi. org/10.17650/2313-805X-2024-11-3-103-113

Authors' information:

Golovkin Ilya Olegovich,
Junior Researcher, Central Research Laboratory, Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University
ORCID ID: 0000-0002-3578-5130
SPIN: 4623-9104
Author ID: 1099671
E-mail: golovkin.io.1996@gmail.com

Aliev Kazim Alievich,
Candidate of Medical Sciences, Associate Professor of the Department of Oncology, Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University
ORCID ID: 0000-0003-3911-1245
SPIN: 5975-5240
Author ID: 778513
E-mail: k8929199@gmail.com

Makalish Tatyana Pavlovna,
Candidate of Biological Sciences, Senior Researcher, Central Research Laboratory, Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University
ORCID ID: 0000-0003-1884-2620
SPIN: 1523-5893
Author ID: 891400
E-mail: gemini_m@list.ru

Asanova Elvina Refatovna,
Junior Researcher, Central Research Laboratory, Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University
ORCID ID: 0009-0001-0409-3297
SPIN: 8110-7701
Author ID: 1210039
E-mail: elyabiolog@yandex.ru

Maksimova Polina Evgenievna,
Junior Researcher, Central Research Laboratory, Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University; Second-Year Resident in Hematology, Pavlov First St. Petersburg State Medical University
ORCID ID: 0000-0001-5920-8664
SPIN: 9734-8508
Author ID: 1156001
E-mail: pmaksq@mail.ru

Zyablitskaya Evgeniya Yurievna,
Doctor of Medical Sciences, Associate Professor, Senior Researcher, Central Research Laboratory, Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University
ORCID ID: 0000-0001-8216-4196
SPIN: 2267-3643
Author ID: 766290
E-mail: evgu79@mail.ru

Information about support in the form of grants, equipment, medications

The study was conducted with financial support from State Assignment FZEG2023-0009, “Study of the heterogeneity of the tumor microenvironment as a factor of its aggressiveness and resistance to therapy”, No. 123030700011-4 dated March 7, 2023. The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Zyablitskaya Evgeniya Yurievna
Doctor of Medical Sciences, Senior Researcher, Central Research Laboratory, Order of the Red Banner of Labour Medical Institute named after S.I. Georgievsky

295051, Russian Federation, Republic of Crimea, Simferopol, Lenin Blvd., 5/7

Tel.: +7 (978) 7434810

E-mail: evgu79@mail.ru


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic:
  1. CLINICAL AND MORPHOLOGICAL FEATURES AND CYTOKINE STATUS ASSESSMENT IN THYROID CANCER
  2. EVALUATION OF THE EFFICIENCY OF COMBINED TREATMENT OF PATIENTS WITH BONE METASTASES FROM KIDNEY AND PROSTATE CANCER USING SYSTEMIC RADIATION AND TARGETED THERAPY
  3. INCIDENCE OF MULTIPLE PRIMARY MALIGNANT NEOPLASMS IN SIBERIA AND THE FAR EAST
  4. SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER: ONGOING CONSIDERATIONS
  5. ROLE OF RADIATION THERAPY IN COMBINED AND MULTIMODAL TREATMENT OF T3-4N1-2-3M0-1-2 STAGE SKIN CANCER
  6. SURGICAL TREATMENT OF A GIANT RETROPERITONEAL LIPOMA: A CLINICAL CASE
  7. PREOPERATIVE PREDICTION OF WALL INVASION DEPTH OF PRIMARY TUMOR (PT) IN GASTRIC CANCER PATIENTS
  8. CURRENT SURGICAL TREATMENT OPTIONS FOR LATE STAGES OF CERVICAL CANCER
  9. METASTATIC HEAD AND NECK CANCER WITH UNKNOWN PRIMARY: DIAGNOSIS AND TREATMENT
  10. CLINICAL CASE OF BCLC STAGE B HEPATOCELLULAR CARCINOMA WITH A COMBINED TREATMENT

◄ Back to the list